When Janice Cowden was diagnosed with metastatic triple-negative breast cancer in 2016, the statistics were bleak. At the time, she recalls seeing a median overall survival estimate of roughly 9 to 15 months and asking herself a simple question: What am I going to do with the time I have?
Instead of stepping away from the uncertainty, Janice stepped into advocacy. A former pediatric nurse with a background in pharmaceutical sales, she completed patient advocacy training and quickly discovered a metastatic breast cancer community she had not even known existed. That experience became the beginning of years of peer support, research advocacy, and education for people living with metastatic disease.
In this episode of The Patient From Hell, Janice returns to discuss how much metastatic triple-negative breast cancer treatment has changed, what the ASCENT-04 trial could mean for first-line treatment, why clinical trial design should include patients from the beginning, and the difficult balance between living longer and living well.
Episode Highlights
- How treatment for metastatic triple-negative breast cancer (mTNBC) has evolved over the past decade, including immunotherapy, PARP inhibitors, and antibody-drug conjugates.
- What the ASCENT-04 trial studied and why its progression-free survival results generated excitement in the metastatic TNBC community.
- Why getting an effective treatment into the first-line setting matters when many patients may never reach a second line of therapy.
- How clinical trial design works, including crossover, and why Janice believes patients should have a voice before a trial is even launched.
- How patients and oncologists can think about quality of life versus quantity of life when treatment may continue indefinitely.
- Janice's hopes for the future: better biomarkers, more precise targets, more effective therapies, and fewer treatment side effects.
About the Guest
Janice Cowden is a metastatic breast cancer patient advocate and retired pediatric nurse whose personal experience has shaped a career focused on research, education, and peer support. She was first diagnosed with stage I triple-negative breast cancer in 2011 and later diagnosed with stage IV metastatic triple-negative breast cancer in 2016. After completing Living Beyond Breast Cancer's Hear My Voice advocacy training in 2017, she became deeply involved in the metastatic breast cancer community.
Today, Janice serves as Director of Peer-to-Peer at METAvivor and works across research and patient advocacy initiatives supporting people living with metastatic breast cancer. She is particularly passionate about helping patients understand clinical research, treatment options, and the importance of finding community and meaningful peer connection.
Pull Quote
“It’s not an immediate death sentence.”
ASCENT-04: Why the Trial Matters
The ASCENT-04/KEYNOTE-D19 study evaluated first-line treatment for people with previously untreated, advanced or metastatic PD-L1-positive triple-negative breast cancer.
The trial compared sacituzumab govitecan plus pembrolizumab with chemotherapy plus pembrolizumab. At the 2025 ASCO Annual Meeting, results showed a median progression-free survival of 11.2 months versus 7.8 months, representing a statistically significant improvement. Median duration of response was also longer with the antibody-drug conjugate combination: 16.5 months versus 9.2 months.
For Janice, the significance goes beyond the numbers. In metastatic TNBC, first-line treatment matters enormously because some patients may never become healthy enough to reach a second-line therapy. Moving a more effective treatment earlier could give patients a longer period of disease control—and potentially more time to reach future treatment options.
An Important Update Since This Episode Was Recorded
The treatment landscape has continued to move quickly. On June 24, 2026, the FDA approved sacituzumab govitecan in combination with pembrolizumab for the first-line treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 with a CPS of 10 or greater, based on ASCENT-04/KEYNOTE-D19.
That means a therapy discussed in this episode as a potential future standard of care has since become an FDA-approved first-line option for the appropriate patient population.
Why Clinical Trial Design Matters to Patients
One of the most compelling parts of the conversation is Janice's discussion of patient involvement in clinical research.
Clinical trials are designed to answer scientific questions, but the way a trial is structured can directly affect the people participating in it. Janice argues that patients and advocates should be involved before decisions are finalized around trial arms, endpoints, procedures, and informed consent.
She points out that researchers may design something that looks efficient on paper but doesn't reflect what is actually meaningful—or practical—for patients. Patient input can uncover concerns that researchers may not otherwise see.
Her perspective is part of a broader push toward making cancer research more patient-centered, from trial design through treatment access.
Quality of Life vs. Quantity of Life
For people living with metastatic cancer, treatment decisions are rarely as simple as choosing the therapy with the largest number attached to it.
Janice describes the goal as finding quantity of life with quality of life. Because metastatic breast cancer is often treated over the long term, side effects, daily function, personal priorities, family responsibilities, and the patient's stage of life all become part of the treatment conversation.
A treatment decision for a parent of young children may look very different from one for someone at another stage of life. The important point is that there is no universal answer. The conversation between a patient and their oncology team has to account for what matters most to that individual.
What Janice Wants Patients to Know
Janice's message to someone newly diagnosed with metastatic triple-negative breast cancer is both realistic and hopeful.
The disease remains aggressive, and compared with other breast cancer subtypes, treatment options are still more limited. But today's landscape is very different from the one she entered in 2016. New therapies have expanded the treatment toolbox, research is moving rapidly, and more clinical trials are exploring ways to identify new targets and improve outcomes.
Her advice is simple: learn your options, ask questions, and stay connected to the research.
Most importantly, don't mistake an aggressive diagnosis for an immediate end.
Resources Mentioned
- METAvivor — Research, advocacy, and peer-to-peer support for metastatic breast cancer: https://metavivor.org/
- Living Beyond Breast Cancer — Patient education and advocacy resources: https://www.lbbc.org/
- ASCENT-04/KEYNOTE-D19 — Clinical trial information and published results.
- FDA — Current information on the first-line approval based on ASCENT-04.
Tags
metastatic triple negative breast cancer, triple negative breast cancer, mTNBC, ASCENT-04, metastatic breast cancer, breast cancer clinical trials, breast cancer treatment, cancer patient advocacy, oncology research, progression free survival, antibody drug conjugates, breast cancer survivorship
